glp 1 agonist clinical trials Summaries of landmark with GLP-1 agonists Evolution of GLP‐1 Receptor Agonists

doi: 10.1016/j.toxicon.2021.09.002 Nixon, Samantha A., Robinson, Samuel D., Agwa, Akello J., Walker, Andrew A., Choudhary, Shivani, Touchard, Axel, Undheim, Eivind A.B., Robertson, Alan, Vetter, Irina, Schroeder, Christina I., Kotze, Andrew C., Herzig, Volker and King, Glenn F

Also read: How Obesity Impacts Your Health MYTH: Anyone Who Wants to Lose Weight Should Take a GLP1 Agonist

Petrylak DP, Tangen CM, Hussain MH, Lara PNJ, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

& Burckhardt, B

Significantly impairing the quality of life for those affected, the prevalence of hyperuricemia is an upward trend globally, especially in most developed countries